IPP Bureau

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
Lupin receives approval from USFDA for Arformoterol Tartrate inhalation

By IPP Bureau - February 08, 2022

Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)

Origin Materials and Minafin form strategic partnership for biobased chemicals
Origin Materials and Minafin form strategic partnership for biobased chemicals

By IPP Bureau - February 08, 2022

The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries

Biosynthetic Technologies raises $7.5 million
Biosynthetic Technologies raises $7.5 million

By IPP Bureau - February 08, 2022

Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.

India grants Emergency Use Authorisation to Sputnik Light
India grants Emergency Use Authorisation to Sputnik Light

By IPP Bureau - February 07, 2022

This is the ninth Covid-19 vaccine approved in India

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

By IPP Bureau - February 07, 2022

Key takeaways of recent quarter & conference call highlights

Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19
Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19

By IPP Bureau - February 07, 2022

ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status

Venus Remedies join AMR alliance to combat global health threat
Venus Remedies join AMR alliance to combat global health threat

By IPP Bureau - February 07, 2022

The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry

Rahul Guha to join Thyrocare Technologies as MD & CEO
Rahul Guha to join Thyrocare Technologies as MD & CEO

By IPP Bureau - February 07, 2022

Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice

WHO Goodwill Ambassador calls for renewed focus on leprosy
WHO Goodwill Ambassador calls for renewed focus on leprosy

By IPP Bureau - February 07, 2022

The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic

Redcliffe Labs appoints Abhay Singavi as Chief Business Officer
Redcliffe Labs appoints Abhay Singavi as Chief Business Officer

By IPP Bureau - February 07, 2022

Takes charge to lead business innovation, strategy, alliance & partnerships

Serum receives green light for Omicron variant vaccine
Serum receives green light for Omicron variant vaccine

By IPP Bureau - February 07, 2022

Pfizer and Moderna are also working on vaccines that target the Omicron variant

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

By IPP Bureau - February 05, 2022

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

By IPP Bureau - February 05, 2022

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore

By IPP Bureau - February 05, 2022

IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

By IPP Bureau - February 05, 2022

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021

Latest Stories

Interviews

Packaging